Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Trandolapril is a prodrug form of the angiotensin-converting enzyme (ACE) inhibitor trandolaprilat (Item No. 29577).1 Trandolapril is converted to trandolaprilat by carboxylesterase 1 (CES1) in human liver microsomes. It inhibits angiotensin I-induced pressor responses in rats and dogs (ID50s = 13.1 and 21.1 μg/kg, respectively) and potentiates the bradykinin-induced depressor response in rats (ED50 = 5.5 μg/kg).2 Trandolapril (0.1, 0.3, and 1 mg/kg) decreases systolic and diastolic arterial pressure in dogs. It decreases mean arterial pressure (MAP) and left ventricular end-diastolic pressure (LVEDP) in a rat model of heart failure induced by left coronary artery occlusion when administered at a dose of 3 mg/kg.3 Trandolapril (0.01 and 1 mg/kg) increases survival in stroke-prone spontaneously hypertensive rats fed a high-salt diet.4 Formulations containing trandolapril have been used in the treatment of hypertension.
WARNING This product is not for human or veterinary use.
1. Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol. 77(7), 1266-1272 (2009).
2. Angiotensin-
3. Effects of long-
4. Trandolapril’s protective effects in stroke-